Macrogen, Inc.

KOSDAQ:A038290 Stock Report

Market Cap: ₩163.9b

Macrogen Past Earnings Performance

Past criteria checks 0/6

Macrogen's earnings have been declining at an average annual rate of -67.3%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 5.6% per year.

Key information

-67.3%

Earnings growth rate

-67.2%

EPS growth rate

Life Sciences Industry Growth53.7%
Revenue growth rate5.6%
Return on equity-14.6%
Net Margin-16.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Macrogen's (KOSDAQ:038290) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 02
Macrogen's (KOSDAQ:038290) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Recent updates

Macrogen, Inc.'s (KOSDAQ:038290) Low P/S No Reason For Excitement

Nov 13
Macrogen, Inc.'s (KOSDAQ:038290) Low P/S No Reason For Excitement

Macrogen, Inc.'s (KOSDAQ:038290) Revenues Are Not Doing Enough For Some Investors

Jul 24
Macrogen, Inc.'s (KOSDAQ:038290) Revenues Are Not Doing Enough For Some Investors

Macrogen's (KOSDAQ:038290) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 02
Macrogen's (KOSDAQ:038290) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Macrogen (KOSDAQ:038290) Has Debt But No Earnings; Should You Worry?

Mar 03
Macrogen (KOSDAQ:038290) Has Debt But No Earnings; Should You Worry?

Reflecting on Macrogen's (KOSDAQ:038290) Share Price Returns Over The Last Three Years

Jan 09
Reflecting on Macrogen's (KOSDAQ:038290) Share Price Returns Over The Last Three Years

Revenue & Expenses Breakdown

How Macrogen makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A038290 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24131,729-21,73044,5534,546
30 Jun 24131,018-20,52643,9364,546
31 Mar 24131,009-20,39543,1984,546
31 Dec 23132,803-16,81440,7984,546
30 Sep 23133,923-22,28640,9774,267
30 Jun 23137,180-18,77841,3514,267
31 Mar 23136,765-20,89240,5634,267
31 Dec 22138,617-22,25340,0894,267
30 Sep 22137,8502,25741,5234,101
30 Jun 22130,77587237,4144,101
31 Mar 22130,2684,21234,8874,101
31 Dec 21129,1751,11232,6334,101
30 Sep 21125,233-12,32127,4176,244
30 Jun 21123,9621,29926,0966,244
31 Mar 21118,03721325,6536,244
31 Dec 20112,6034,26726,0226,244
30 Sep 2095,78719,62721,9336,183
30 Jun 2098,4834,34123,9536,183
31 Mar 20101,85210,52723,5966,183
31 Dec 19102,81517,89223,4256,183
30 Sep 19120,20812,05926,8106,679
30 Jun 19115,15012,48825,8086,679
31 Mar 19115,6399,10426,3696,679
31 Dec 18112,8312,64525,3416,679
30 Sep 18108,57512,55026,5925,188
30 Jun 18107,95913,22824,9145,188
31 Mar 18104,46214,17324,4575,188
31 Dec 17101,7939,52923,6205,188
30 Sep 1798,4721,66123,1164,930
30 Jun 1794,772-55821,6624,930
31 Mar 1792,395620,8364,930
31 Dec 1691,1134,30120,0814,930
30 Sep 1688,2077,04917,6914,178
30 Jun 1690,66311,89517,8774,178
31 Mar 1687,03011,50816,7774,178
31 Dec 1579,53410,17216,5224,178
30 Sep 1573,9264,74618,4823,385
30 Jun 1563,1162,81217,1523,385
31 Mar 1558,0902,43516,3483,385
31 Dec 1454,1302,98914,3133,385
30 Sep 1450,1075,43118,197390
30 Jun 1448,6885,64116,6711,117
31 Mar 1448,4376,43715,1231,936

Quality Earnings: A038290 is currently unprofitable.

Growing Profit Margin: A038290 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A038290 is unprofitable, and losses have increased over the past 5 years at a rate of 67.3% per year.

Accelerating Growth: Unable to compare A038290's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A038290 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (39.6%).

Return on Equity

High ROE: A038290 has a negative Return on Equity (-14.61%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 17:04
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Macrogen, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Song-hyup HanDaishin Securities Co. Ltd.
Sang-Hun LeeiM Securities
Jaehoon ChoiKorea Investment & Securities Co., Ltd.